U.S. Intrauterine Devices Market Size By Product (Copper IUD, Hormonal IUD), By Age Group (15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45+), Industry Analysis Report, Zonal Outlook (East North Central (Illinois, Indiana, Michigan, Ohio, Wisconsin), West Sou

U.S. Intrauterine Devices Market Size By Product (Copper IUD, Hormonal IUD), By Age Group (15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45+), Industry Analysis Report, Zonal Outlook (East North Central (Illinois, Indiana, Michigan, Ohio, Wisconsin), West South Central (Arkansas, Louisiana, Oklahoma, Texas), South Atlantic (Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Washington, D.C.), North East (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, Pennsylvania), East South Central (Alabama, Kentucky, Mississippi, Tennessee), West North Central (Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota), Pacific Central (Alaska, California, Hawaii, Oregon, Washington), Mountain States (Arizona, Colorado, Utah, Nevada, New Mexico, Idaho, Montana, Wyoming)), Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2030

The U.S. intrauterine devices market is slated to record lucrative growth through 2030 owing to an increase in the rate of unwanted pregnancies. In addition, technological advancements in the field of contraceptives with less risk of side effects are likely to further expand market deployment over the forecast timeline.

Intrauterine devices (IUDs) are the most effective form of reversible contraception. IUDs are small devices placed in the uterus through the cervix by a trained medical practitioner to avoid pregnancies. To curb unwanted pregnancies and prevent maternal fatalities, improvising access to reproductive health and family planning services across the world is vital. Recently, supportive government initiatives and increasing focus of private firms on providing client-centered contraceptive services to avoid unwanted abortions and the risk of sexually transmitted diseases have also contributed to the expansion of the U.S. intrauterine devices market.

Notably, the United States government broadly supports these services and is one of the largest distributors and purchasers of contraceptives globally. Intrauterine devices offer benefits like easy usability, cost-effectiveness, long durability, and easy maintenance, which have propelled their adoption across the United States, fueling overall market progress.

Over the years, there has been a tremendous increase in the number of working women, and with that, the trend of planned and delayed pregnancies has emerged. Additionally, rising awareness of IUDs across the country has also contributed to market growth.

The U.S. intrauterine devices market has been bifurcated in terms of product, age group, and zone. With reference to product, the market has been divided into copper IUD and hormonal IUD. In 2021, the copper IUD segment was valued at over USD 224 million and is anticipated to grow at the rate of approximately 7.1% through the forecast period due to soaring demand and rising awareness regarding the benefits offered by copper IUD in preventing pregnancy.

On the basis of age group, the U.S. intrauterine devices market has been bifurcated into 20-24, 25-29, 15-19, 30-34, 40-44, 35-39, and 45+. The 20-24 age group segment reached about USD 205 million in revenue in 2021 and is likely to exhibit substantial growth at a rate of over 10.4% from 2022 to 2030. Increasing awareness among 20–24 age group females about various IUD applications and the consequences of unintended pregnancies is set to foster segmental outlook.

By zone, the U.S. intrauterine devices market spans the regions of West South Central, East North Central, East South Central, South Atlantic, North East, West North Central, Mountain States, and Pacific Central. In 2021, the East North Central intrauterine devices market garnered a valuation of more than USD 174 million and is anticipated to record a CAGR of about 10.6% through the forecast timespan owing to a favorable regulatory scenario and surging inclination toward planned delayed pregnancy.